---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-017858"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:15:18.797172+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend

## Summary
- Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.
- First IV TPOXX sales to U.S. govt under BARDA contract: $7M delivered in Q1.
- New Asia Pacific contract for ~$3M of oral TPOXX; PHAC contract increased $5M.
- Board declared special dividend of $0.45/share, payable June 2 to holders of record May 17.
- EMA approved oral tecovirimat for smallpox, monkeypox, cowpox, and vaccinia complications.

## SEC filing metadata
- accession: 0001140361-22-017858
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036122017858/0001140361-22-017858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036122017858/brhc10037201_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-017858
- JSON: https://secwatch.observer/filing/0001140361-22-017858.json
- Plain text: https://secwatch.observer/filing/0001140361-22-017858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.